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  ABSTRACT  
llogeneic hematopoietic stem cell transplantation is the optimal 
care for patients with high-risk or intermediate - acute myeloid 
leukemia. In patients lacking matched sibling donor, haploiden- 
tical donors are an option. We compared outcomes of unmanipulated 
(Haplo) to matched sibling donor transplant in acute myeloid leukemia 
patients in first complete remission. Included were intermediate and 
high-risk acute myeloid leukemia in first complete remission undergo- 
ing Haplo and matched sibling donor transplant from 2007-2015, and 
reported to the ALWP of the EBMT. A propensity score technique was 
used to confirm results of main analysis: 2 matched sibling donors 
were matched with 1 Haplo. We identified 2654 pts (Haplo =185; 
matched sibling donor =2469), 2010 with intermediate acute myeloid 
leukemia (Haplo=122; matched sibling donor =1888) and 644 with 
high-risk acute myeloid leukemia (Haplo =63; matched sibling donor 
=581). Median follow up was 30 (range 1-116) months. In multivariate 
analysis, in intermediate - acute myeloid leukemia patients, Haplo 
resulted in lower leukemia-free survival (Hazard Ratio 1.74; P<0.01), 
overall-survival (HR 1.80; P<0.01) and GvHD-free-relapse-free survival 
(Hazard Ratio 1.32; P<0.05) and higher graft-versus-host disease 
(GvHD) non-relapse mortality (Hazard Ratio 3.03; P<0.01) as com- 
pared to matched sibling donor. In high-risk acute myeloid leukemia, 
no differences were found in leukemia-free survival, overall-survival, 
and GvHD-free- relapse-free survival according to donor type. Higher 
 
 
 grade II-IV acute GvHD was observed for Haplo in both high-risk 
(Hazard Ratio 2.20; P<0.01) and intermediate risk (Hazard Ratio 1.84; 
P<0.01). A trend for a lower Relapse-Incidence was observed in 
Haplo among high-risk acute myeloid leukemia (Hazard Ratio 0.56; 
P=0.06). The propensity score analysis confirmed results. Our results 
underline that matched sibling donor is the first choice for acute 
myeloid leukemia patients in first complete remission. On the other 
hand, results of Haplo transplants are similar to matched sibling 
donor transplants in acute myeloid leukemia patients with high risk 
cytogenetics. 
 
 
 
 
Introduction 
Allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) is a potentially curative treatment for 
patients with acute myeloid leukemia (AML).1 However, 
a human leukocyte antigen (HLA)-identical sibling2,3 is 
available in only 25-35% of the patients.4 For patients 
lacking a full matched sibling donor (MSD), other stem 
cell sources are available such as unrelated donors,5 
umbilical cord blood units,6 or HLA-mismatched family 
donors (Haplo).7,8 The advantage of the latter is the rapid 
availability of the donors both for the transplant proce- 
dure and for subsequent adoptive immunotherapies. 
Initial concerns with the Haplo-HSCT were the high rate 
of graft failure, of severe graft-versus-host disease (GvHD) 
due to the multiple class I and II HLA disparities between 
donor and recipient, and the high non-relapse mortality 
(NRM).9,10,11 Advances in HLA typing, optimization of 
GvHD prophylaxis and other transplantation techniques 
allowed outcome improvements,8 such as the use of non 
T-cell depleted (TCD) unmanipulated grafts with new 
strategies to modulate donor T-cell alloreactivity. In par- 
ticular, the use of post-transplant high-dose cyclophos- 
phamide (PTCY) or the addition of anti thymocyte glob- 
ulin (ATG) to standard GvHD prophylaxis ensured higher 
rates of engraftment while keeping an acceptable inci- 
dence of GvHD.12,13,14 
This contributed to the increase in the number of 
unmanipulated Haplo-HSCT performed in recent years.15 
Single center or registry-based studies have reported 
similar outcomes between Haplo-HSCT and unrelated or 
cord blood allo-HSCT for patients with hematological 
malignancies.14,16,17,18 
Data comparing Haplo -HSCT to MSD-HSCT in AML 
patients are limited. In a recent prospective multicenter 
non-randomized study from China, Wang et al.19 showed 
in a very young cohort of AML patients (median age of 28 
years in the Haplo group) similar outcomes for Haplo and 
MSD-HSCT in AML patients in first complete remission 
(CR1). Similarly, Yoon et al.20 analyzed long-term out- 
comes of 561 patients with intermediate (n=417) or poor 
risk (n=144) AML that underwent HSCT in CR1 from 
various donors including from MSD and Haplo. In poor 
risk AML, the authors observed a 5-year disease-free sur- 
vival (DFS) of 47% versus 60% (P<0.01) for MSD and 
Haplo, respectively; while in intermediate risk AML, DFS 
was 66% and 68% (P=0.08) for MSD and Haplo, respec- 
tively. 
Herein, we conducted a registry-based study of adult 
patients undergoing either an unmanipulated Haplo or a 
MSD allo-HSCT for high or intermediate risk AML in 
CR1, reported to the Acute Leukemia Working Party 
(ALWP) of EBMT. 
 
Methods 
We retrospectively analyzed adult patients ( 18 years) diag- 
nosed with AML with intermediate or unfavorable cytogenetics 
who underwent their first allo-HSCT in CR1 between 2007 and 
2015, from either a MSD or Haplo donor, and whose data were 
reported to the ALWP of the EBMT. 
The EBMT is a voluntary working group of more than 500 
transplant centers that are required to report all consecutive stem 
cell transplantations and follow up once a year. Audits are routine- 
ly performed to determine the accuracy of the data. This study 
was approved by the ALWP of the EBMT institutional review 
board and conducted in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines. 
Patients were stratified according to cytogenetic status at diag- 
nosis in intermediate or high risk, according to the previous defi- 
nition from Grimwade et al.21 Of note, included in the Haplo 
group, were only patients receiving an unmanipulated graft with 
the use of in vivo TCD or PTCY. Ex vivo graft manipulation was an 
exclusion criteria. 
Conditioning regimen was defined myeloablative (MAC) when 
containing total body irradiation (TBI) with a dose >6 Gray or a 
total dose of busulfan (Bu) >8 mg/kg or >6.4 mg/kg when admin- 
istered orally or intravenously, respectively. All other regimens 
were defined as RIC.22 
Primary end-point was leukemia-free survival (LFS), defined as 
the probability of being alive and disease-free at any time point. 
Both death and relapse were considered events. Patients alive and 
in CR were censored at their last follow up. Overall survival (OS) 
was defined as the probability of being alive at any time point. 
Other secondary endpoints were engraftment, acute (aGvHD) and 
chronic (cGvHD) GvHD, relapse incidence (RI), non-relapse mor- 
tality (NRM) and refined graft-versus-host/relapse free survival 
(GRFS),23 defined as being alive with neither grade III-IV aGvHD, 
severe cGvHD nor disease relapse at any time point. Modified 
Glucksberg criteria and revised Seattle criteria were used to grade 
aGvHD24 and cGvHD,25 respectively. Engraftment was defined as 
achieving an absolute neutrophil count greater than or equal to 
0.5×109/L for three consecutive days. NRM was defined as death 
from any cause without previous relapse or progression. Median 
values and ranges were used for continuous variables and percent- 
ages for categorical variables. Patient-, disease- and transplant- 
related variables were compared using 2  or Fischer exact test for 
categorical variables, and Mann–Whitney test for continuous vari- 
ables. Probabilities of OS, LFS and GRFS were calculated using 
Kaplan-Meier method.26 Cumulative incidence functions (CIF) 
were used to estimate RI and NRM in a competing risks setting. 
To study GvHD, death and relapse were considered as competing 
events. Univariate analyses were performed using the log rank test 
for OS, LFS and GRFS, while the Gray test was used for CIF. 
Multivariate analyses adjusted for differences between the groups 
were performed using Cox proportional hazards regression 
model.27 
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All interactions between donor type and other covariates were Results 
tested; a significant interaction according to cytogenetics has been 
found, thus a stratification (intermediate or high cytogenetics risk Patients, disease and transplant characteristics 
AML) with two separate analysis was made.   Patients and transplant characteristics are summarized 
Propensity  score  matching  was also  performed to reduce or in Table 1. Median follow up was 22 (range 3-96) months 
eliminate  confounding  effects.  Two  MSD  were matched with  and 31 (range 1-116) months for Haplo and MSD, respec- 
each  Haplo  using  the  nearest  neighbor  or  exact  matching.28  tively (P<0.01). We identified a total of 2654 patients 
Matching was done without replacement. Included in the propen-  (Haplo=185; MSD=2469), including 2010 intermediate 
sity score model were: age, year of allo-HSCT, time from diagno-  AML (Haplo=1122; MSD=1888) and 644 high risk-AML 
sis to allo-HSCT, conditioning regimen (RIC), source of stem cells,  (Haplo=163; MSD=581) transplanted in 227 EBMT cen- 
cytogenetics, patient and donor CMV serology status.  ters. Median age at allo-HSCT was 50 (range 18-74) years 
All tests were two-sided and P values < 0.05  were considered for both Haplo and MSD (P=0.63). There were some dif- 
statistically significant. Analyses were performed using the R sta-  ferences between the two groups: Haplo underwent allo- 
tistical software version 3.2.3 (available online at http://www.R-  HSCT more recently compared to MSD recipients (2014 
project.org), and propensity score analysis was performed using  versus 2010; P<0.01) and had a longer time from diagnosis 
the ‘MatchIt’.29  to allo-HSCT (6 versus 5 months, P<0.01); furthermore, in 
 
 
Table 1. Patient, disease and transplant characteristics. 
Characteristic (%) Haplo (n=185) MSD (n=2469) P 
Median age, years (range) 50 (18-74) 50 (18-75) 0.63 
Median year of allo-HSCT (range) 2014 (2007-2015) 2010 (2007-2015) <0.01 
Interval from diagnosis to allo-HSCT, months (range) 6 (1-17) 5 (1-18) <0.01 
Cytogenetics 
Intermediate 122 (66) 1888 (76) <0.01 
High risk 63 (34) 581 (24) 
Patient’s sex 
Male 103 (56) 1296 (53) 0.41 
Female 82 (44) 1172 (47) 
Donor’s sex 
Male 96 (52) 1322 (54) 0.43 
Female 89 (48) 1140 (46) 
Patient CMV serostatus 
Negative 28 (15) 777 (32) <0.01 
Positive 155 (85) 1660 (68) 
Donor CMV serostatus 
negative 51 (28  ) 927 (38 ) <0.01 
positive 132 (72 ) 1492 (62 ) 
Missing 2 50 
Conditioning regimen 
MAC 93 (50) 1302 (53) 0.52 
RIC 92 (50) 1167 (47) 
Stem cell source 
BM 92 (50) 473 (19) <0.01 
PBSC 93 (50) 1996 (81) 
GVHD prophylaxis <0.01 
CsA alone 4 (2) 470 (19) 
CsA + MMF 4 (2) 487 (20) 
Csa + MTX 7 (4) 1273 (51) 
PT-CY 137 (74) 36 (2) 
Other 33 (18) 182 (7) 
Missing 0 21 (1) 
In vivo TCD 54 (31) 863 (35) 0.30 
Median follow-up, months (range) 22 (3-96) 31 (1- 116) <0.01 
 
Haplo: haploidentical family donor; MSD: matched sibling donor; allo-HSCT: allogeneic hematopoietic stem cell transplantation; CMV: cytomegalovirus; 
MAC: myeloablative conditioning regimen; RIC: reduced intensity conditioning regimen; BM: bone marrow; PBSC: peripheral blood stem cells; CSA: 
cyclosporine; MMF: mycophenolate mofetil; MTX: methotrexate; PT-CY: post-transplant cyclophosphamide; TCD: in vivo T-cell depletion. 
 
 
  
 
the Haplo group there was a higher proportion of high- 
risk AML (34% versus 24% in MSD, P<0.01), bone mar- 
row (BM) as stem cell source (50% versus 19% in MSD; 
P<0.01) and CMV positive donors (72% versus 62% in 
MSD; P<0.01). Conditioning regimen was MAC in 
approximately 50% of cases in both Haplo and MSD 
(P=0.52). In the Haplo group, the most frequently used 
MAC contained Thiotepa-Busulfan-Fludarabine, while 
the most frequent RIC contained cyclophosphamide and 2 
or 4 Gy TBI. In the MSD group, the most frequently used 
MAC and RIC regimen were Busulfan- 
Cyclophosphamide and Busulfan-Fludarabine, respective- 
ly. Details on conditioning regimens are reported in the 
Online Supplementary Table. Among Haplo recipients, 
137 (74%) received PTCY and 54 (31%) received ATG as 
GvHD prophylaxis. 
Univariate analysis for the whole population 
The results of univariate analysis are summarized in 
Table 2A. A higher engraftment rate was observed in 
MSD recipients (99% versus 96%, P<0.01), with a shorter 
median time to engraftment in this group (16 versus 18 
days in Haplo, P<0.01) 
Higher incidence of grade II-IV aGvHD was found in 
Haplo (21% versus 31%, P<0.01) while cGvHD was lower 
as compared to MSD (33% versus 35%, P=0.05). Main 
causes of death were  disease  recurrence  (in  30% 
versus 59%), GvHD in 16% versus 18% and infections in 
33% versus 12% of Haplo and MSD, respectively. 
At 2 years, CI of relapse was 19% versus 24% (P=0.10) 
and NRM was 23% versus 10% (P<0.01) in Haplo and 
MSD recipients, respectively. The probability of LFS and 
OS were 58% versus 67% (P<0.01) and 68% versus 76% 
(P<0.01), in Haplo and MSD, respectively. Probability of 
GRFS was 47% versus 50% (P=0.25), respectively. 
Multivariate analysis for the whole population 
In a multivariate analysis adjusted on the main differ- 
ences between the two groups (Table 3A), Haplo was 
associated with a higher risk of grade II-IV aGvHD 
(HR=1.94; 95% CI: 1.38-2.73; P<0.01), a higher NRM 
(HR=2.56; 95% CI:1.73-3.77; P<0.01), a lower LFS 
(HR=1.33; 95% CI: 1.03-1.71; P<0.04) and a lower OS 
(HR=1.34; 95% CI: 1.03-1.75; P<0.04). 
Moreover, due to a significant interaction between 
donor type and cytogenetic risk on LFS (P<0.01), all fur- 
ther analyses were stratified on cytogenetic group. 
 
Outcomes according to cytogenetics: intermediate and 
high-risk AML 
Intermediate risk AML 
The results of univariate analysis in this group are sum- 
marized in Table 2B. Grade II-IV aGvHD was 29% versus 
20% (P<0.03) for Haplo and MSD recipients, respectively. 
At 2 years, CI of cGvHD was 30% versus 36% (P<0.02) for 
Haplo and MSD recipients, respectively. The probability 
of LFS and OS were 56 % versus 70% (P<0.01) and 68% 
versus 79% (P<0.01) in Haplo and MSD, respectively. 
Probability of GRFS was 45% versus 54% (P<0.05), in 
Haplo and MSD, respectively. CI of relapse was 18% ver- 
sus 20% (P=0.52) and NRM was 26% versus 10% (P<0.01) 
in Haplo and MSD recipients, respectively. 
In multivariate analysis, Haplo was associated with a 
higher risk of grade II-IV aGvHD (HR 1.84; 95% CI 1.20- 
2.82; P<0.01), higher NRM (HR 3.03; 95% CI 1.98-4.62; 
P<0.01), lower LFS (HR 1.74; 95% CI 1.30-2.32; P<0.01), 
OS (HR 1.80; 95% CI 1.32-2.45; P<0.01) and GRFS (HR 
1.32 ; 95% CI 1.01-1.72; P<0.05). No significant differences 
were found for cGvHD and RI. Results of multivariate 
analysis for donor type and other factors associated with 
the main outcomes are reported in table 3B. 
High risk AML 
The results of univariate analysis are summarized in 
table 2C For Haplo and MSD recipients, grade II-IV 
aGvHD was 36% versus 24% (P<0.04) and cGvHD was 
 
 
 
Table 2. Results of univariate analysis for main outcomes at 2 years after allo-HSCT according to donor type (A) in patients with intermediate (B) 
and high risk (C) AML. 
 
A) Outcome RI % NRM % LFS % OS % Gr. II-IV aGvHD % cGvHD% GRFS% 
 ±s.d. ±s.d. ±s.d. ±s.d. ±s.d. ±s.d. ±s.d. 
Haplo 19±6 23±6 58±6 68±6 31±7 33±6 47±8 
MSD 24±2 10±2 67±4 76±2 21±2 35±2 50±2 
P 0.10 <0.01 <0.01 <0.01 <0.01 0.05 0.25 
B) Outcome RI % NRM % LFS % OS % Gr. II-IV aGvHD % cGvHD% GRFS% 
 ±s.d. ±s.d. ±s.d. ±s.d. ±s.d. ±s.d. ±s.d. 
Haplo 18±7 26±8 56±9 68±8 29±8 30±9 45±9 
MSD 20±3 10±2 70±2 79±2 20±2 36±2 54±2 
P 0.52 <0.01 <0.01 <0.01 <0.03 <0.02 <0.05 
C) 2-years outcome RI% NRM% LFS% OS % aGvHD gr II-IV % cGvHD % GRFS % 
 ±s.d ±s.d ±s.d ±s.d ±s.d ±s.d ±s.d 
Haplo 21±9 18±9 61±13 67±12 36±12 39±12 49±13 
MSD 36±4 10±3 55±4 66±4 24±3 33±4 40±4 
P <0.02 0.16 0.14 0.26 <0.04 0.79 0.17 
RI: relapse incidence; s.d.: standard deviation; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS: refined graft-versus-
host disease/relapse free survival; aGvHD: acute graft-versus-host disease; cGvHD: chronic-graft-versus host disease; Haplo: haploidentical donor; MSD: 
matched sibling donor. 
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39% versus 33% (P=0.79). The probability of LFS and OS In multivariate analysis, Haplo was associated with a 
were 61 % versus 55% (P=0.14) and 67% versus 66% higher risk of grade II-IV aGvHD (HR 2.20; 95% CI 1.29- 
(P=0.26) in Haplo and MSD, respectively. Probability of 3.74; P<0.01) and a trend for a lower RI (HR 0.56; 95% CI 
GRFS was 49% versus 40% (P=0.17), in Haplo and MSD, 0.31-1.01; P=0.06). No significant differences were found 
respectively. CI of relapse was 21% versus 36% (P<0.02)  for other outcomes. Results of multivariate analysis for  
and NRM was 18% versus 10% (P=0.16) for Haplo and donor type and other factors associated with the  main 
MSD, respectively. outcomes are reported in table 3C. 
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Figure 1. Outcomes at two years according to pair-matched analysis in patients with intermediate-risk acute myeloid leukemia. (A) Relapse-incidence. (B) Non- 
relapse mortality. (C Leukemia-free survival. (D) Overall survival. 
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Figure 2. Outcomes at two years according to pair-matched analysis in patients with high-risk acute myeloid leukemia. (A) Relapse-incidence. (B) Non-relapse 
mor- tality. (C) Leukemia-free survival. (D) Overall survival. 
haematologica | 2018; 103(8) 1321 
  
 
 
Table 3. Results of multivariate analysis of main outcomes after HSCT in the entire population (A) and in patients with intermediate (B) or high 
risk (c) AML. 
A) Variable HR (95% CI) P 
RI 
Haplo versus. MSD 0.86 (0.60-1.22) 0.41 
Age (incremental age of 10 years) 1.03 (0.97-1.11) 0.27 
Year of allo-HSCT 1.00 (0.97-1.04) 0.62 
RIC versus MAC 1.12 (0.93-1.34) 0.21 
PBSC versus BM 0.95 (0.78-1.17) 0.66 
Female to male recipient versus other 0.91 (0.76-1.09) 0.33 
Patient CMV seropositivity 1.07 (0.90-1.27) 0.43 
Donor CMV seropositivity 0.90 (0.76-1.05) 0.20 
Poor cytogenetics versus other 1.90 (1.62-2.22) <0.01 
Time from diagnosis to allo-HSCT > median 0.94 (0.90-0.98) <0.01 
NRM 
Haplo versus MSD 2.56 (1.73-3.77) <0.01 
Age (incremental age of 10 years) 1.24 (1.11-1.37) <0.01 
Year of allo-HSCT 0.96 (0.92-1.01) 0.17 
RIC versus MAC 0.79 (0.61-1.03) 0.08 
PBSC versus BM 0.98 (0.73-1.31) 0.89 
Female to male recipient versus other 1.33 (1.05-1.67) 0.01 
Patient CMV seropositivity 1.22 (0.93-1.59) 0.13 
Donor CMV seropositivity 1.28 (1.00-1.64) 0.04 
Poor cytogenetics versus other 1.03 (0.79-1.34) 0.79 
Time from diagnosis to allo-HSCT > median 1.00 (0.96-1.05) 0.76 
LFS 
Haplo versus MSD 1.33 (1.03-1.71) <0.04 
Age (incremental age of 10 years) 1.09 (1.03-1.16) <0.01 
Year of allo-HSCT 0.99 (0.97-1.02) 0.76 
RIC versus MAC 1.00 (0.86-1.16) 0.93 
PBSC versus BM 0.96 (0.81-1.13) 0.65 
Female to male recipient versus other 1.04 (0.91-1.20) 0.50 
Patient CMV seropositivity 1.11 (0.96-1.29) 0.13 
Donor CMV seropositivity 1.00 (0.87-1.15) 0.94 
Poor cytogenetics versus other 1.59 (1.39-1.81) <0.01 
Time from diagnosis to allo-HSCT > median 0.97 (0.94-1.00) 0.08 
OS 
Haplo versus MSD 1.34 (1.03-1.75) <0.04 
Age (incremental age of 10 years) 1.15 (1.08-1.22) <0.01 
Year of allo-HSCT 0.99 (0.96-1.02) 0.71 
RIC versus MAC 0.94 (0.81-1.09) 0.45 
PBSC versus BM 1.04 (0.88-1.23) 0.60 
Female to male recipient versus other 1.09 (0.94-1.27) 0.21 
Patient CMV seropositivity 1.15 (0.99-1.34) 0.06 
Donor CMV seropositivity 1.01 (0.87-1.16) 0.87 
Poor cytogenetics versus other 1.71 (1.49-1.97) <0.01 
Time from diagnosis to allo-HSCT > median 0.97 (0.94-1.01) 0.17 
GRFS 
Haplo versus MSD 1.17 (0.92-1.48) 0.18 
Age (incremental age of 10 years) 1.07 (1.01-1.12) <0.01 
Year of allo-HSCT 0.98 (0.96-1.00) 0.12 
RIC versus MAC 0.90 (0.79-1.03) 0.14 
PBSC versus BM 1.07 (0.92-1.24) 0.36 
 
continued on the next page 
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LFS 
Haplo versus MSD 1.74 (1.30-2.32) <0.01 
Age (incremental age of 10 years) 1.08 (1.01-1.16) <0.04 
Year of allo-HSCT 1.01 (0.98-1.04) 0.59 
continued on the next page 
 
 
Female to male recipient versus other 1.20 (1.07-1.36) <0.01 
Patient CMV seropositivity 1.04 (0.92-1.18) 0.47 
Donor CMV seropositivity 1.03 (0.92-1.16) 0.55 
Poor cytogenetics versus other 1.40 (1.24-1.58) <0.01 
Time from diagnosis to allo-HSCT > median 0.98 (0.95-1.00) 0.17 
aGvHD II-IV 
Haplo versus MSD 1.94 (1.38-2.73) <0.01 
Age (incremental age of 10 years) 1.00 (0.92-1.08) 0.98 
Year of allo-HSCT 0.96 (0.92-0.99) 0.02 
RIC versus MAC 0.69 (0.55-0.86) <0.01 
PBSC versus BM 0.98 (0.77-1.24) 0.87 
Female to male recipient versus other 1.31 (1.08-1.59) <0.01 
Patient CMV seropositivity 0.83 (0.67-1.02) 0.09 
Donor CMV seropositivity 1.17 (0.96-1.43) 0.11 
Poor cytogenetics versus other 1.23 (1.01-1.50) 0.03 
Time from diagn to allo-HSCT > median 0.95 (0.91-1.00) 0.04 
cGvHD 
Haplo versus MSD 0.80 (0.57-1.13) 0.21  
Age (incremental age of 10 years) 1.09 (1.02-1.16) <0.01  
Year of allo-HSCT 0.99 (0.96-1.02) 0.88  
RIC versus MAC 0.77 (0.65-0.92) <0.01  
PBSC versus BM 1.15 (0.94-1.40) 0.16  
Female to male recipient versus other 1.42 (1.22-1.65) <0.01  
Patient CMV seropositivity 0.92 (0.78-1.07) 0.31  
Donor CMV seropositivity 1.05 (0.91-1.23) 0.46  
Poor cytogenetics versus other 1.04 (0.88-1.22) 0.62  
Time from diagnosis to allo-HSCT > median 0.99 (0.96-1.02) 0.76  
B) Variable HR (95% CI) P 
RI    
Haplo versus MSD 1.12 (0.74-1.71) 0.58  
Age (incremental age of 10 years) 0.99 (0.91-1.08) 0.80  
Year of allo-HSCT 1.01 (0.98-1.05) 0.47  
RIC versus MAC 1.25 (1.01-1.57) <0.05  
PBSC versus BM 0.98 (0.78-1.24) 0.86  
Female to male recipient versus other 0.87 (0.70-1.08) 0.20  
Patient CMV seropositivity 0.99 (0.80-1.22) 0.93  
Donor CMV seropositivity 1.06 (0.87-1.30) 0.55  
Time from diagnosis to allo-HSCT > median 0.94 (0.89-0.98) <0.01  
NRM    
Haplo versus MSD 3.03 (1.98-4.62) <0.01  
Age (incremental age of 10 years) 1.27 (1.12-1.43) <0.01  
Year of allo-HSCT 0.99 (0.94-1.05) 0.85  
RIC versus MAC 0.86 (0.64-1.15) 0.30  
PBSC versus BM 1.11 (0.80-1.53) 0.54  
Female to male recipient versus other 1.29 (1.00-1.67) 0.06  
Patient CMV seropositivity 1.15 (0.86-1.55) 0.35  
Donor CMV seropositivity 1.41 (1.06-1.87) <0.02  
Time from diagnosis to allo-HSCT > median 0.99 (0.94-1.04) 0.69  
D. Salvatore et al. 
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RIC versus MAC 1.09 (0.92-1.30) 0.32 
PBSC versus BM 1.02 (0.85-1.23) 0.82 
Female to male recipient versus other 1.02 (0.87-1.20) 0.80 
Patient CMV seropositivity 1.04 (0.88-1.24) 0.63 
Donor CMV seropositivity 1.17 (0.99-1.38) 0.06 
Time from diagnosis to allo-HSCT > median 0.96 (0.93-1.00) <0.04 
OS   
Haplo versus MSD 1.80 (1.32-2.45) <0.01 
Age (incremental age of 10 years) 1.14 (1.06-1.23) <0.01 
Year of allo-HSCT 1.01 (0.97-1.04) 0.72 
RIC versus MAC 1.01 (0.84-1.22) 0.91 
PBSC versus BM 1.13 (0.92-1.38) 0.25 
Female to male recipient versus other 1.09 (0.92-1.30) 0.33 
Patient CMV seropositivity 1.10 (0.92-1.32) 0.30 
Donor CMV seropositivity 1.15 (0.96-1.37) 0.13 
Time from diagnosis to allo-HSCT > median 0.94 (0.93-1.01) 0.13 
GRFS   
Haplo versus MSD 1.32 (1.01-1.72) <0.05 
Age (incremental age of 10 years) 1.07 (1.01-1.13) <0.03 
Year of allo-HSCT 0.99 (0.96-1.02) 0.44 
RIC versus MAC 0.97 (0.83-1.13) 0.68 
PBSC versus BM 1.02 (0.87-1.20) 0.77 
Female to male recipient versus other 1.22 (1.06-1.40) <0.01 
Patient CMV seropositivity 1.06 (0.91-1.22) 0.46 
Donor CMV seropositivity 1.16 (1.01-1.33) <0.04 
Time from diagnosis to allo-HSCT > median 0.97 (0.95-1.01) 0.11 
aGvHD II-IV   
Haplo versus MSD 1.84 (1.20-2.82) <0.01 
Age (incremental age of 10 years) 1.05 (0.95-1.16) 0.32 
Year of allo-HSCT 0.96 (0.92-1.00) 0.06 
RIC versus MAC 0.65 (0.50-0.85) <0.01 
PBSC versus BM 0.90 (0.68-1.18) 0.44 
Female to male recipient versus other 1.47 (1.18-1.84) <0.01 
Patient CMV seropositivity 0.81 (0.64-1.04) 0.10 
Donor CMV seropositivity 1.32 (1.03-1.69) <0.03 
Time from diagn to allo-HSCT > median 0.96 (0.91-1.01) 0.12 
cGvHD     
Haplo versus MSD 0.75 (0.50-1.13) 0.17   
Age (incremental age of 10 years) 1.10 (1.02-1.19) <0.02   
Year of allo-HSCT 1.00 (0.97-1.03) 0.99   
RIC versus MAC 0.73 (0.60-0.89) <0.01   
PBSC versus BM 1.18 (0.94-1.48) 0.15   
Female to male recipient versus other 1.48 (1.25-1.74) <0.01   
Patient CMV seropositivity 0.94 (0.78-1.12) 0.47   
Donor CMV seropositivity 1.07 (0.90-1.27) 0.45   
Time from diagnosis to allo-HSCT > median 1.00 (0.97-1.04) 0.7   
c) Variable HR (95% CI) P  
RI     
Haplo versus MSD 0.56 (0.31-1.01) 0.06   
Age (incremental age of 10 years) 1.16 (1.03-1.29) <0.02   
Year of allo-HSCT 1.00 (0.95-1.05) 0.94   
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continued from the previous page     
RIC versus MAC 0.88 (0.66-1.18) 0.41  
PBSC versus BM 0.85 (0.60-1.20) 0.36  
Female to male recipient vs. other 0.99 (0.74-1.34) 0.97  
Patient CMV seropositivity 1.19 (0.90-1.59) 0.22  
Donor CMV seropositivity 0.66 (0.51-0.86) <0.01  
Time from diagnosis to allo-HSCT > median 0.95 (0.88-1.03) 0.20  
NRM    
Haplo versus MSD 1.40 (0.62-3.13) 0.41  
Age (incremental age of 10 years) 1.17 (0.95-1.43) 0.12  
Year of allo-HSCT 0.88 (0.79-0.97) 0.01  
RIC versus MAC 0.57 (0.33-0.97) 0.04  
PBSC versus BM 0.70 (0.39-1.24) 0.22  
Female to male recipient versus other 1.49 (0.90-2.46) 0.12  
Patient CMV seropositivity 1.56 (0.87-2.77) 0.13  
Donor CMV seropositivity 0.95 (0.57-1.56) 0.83  
Time from diagnosis to allo-HSCT > median 1.08 (0.98-1.19) 0.11  
LFS    
Haplo versus MSD 0.73 (0.46-1.17) 0.19  
Age (incremental age of 10 years) 1.16 (1.05-1.28) <0.01  
Year of allo-HSCT 0.97 (0.93-1.02) 0.21  
RIC versus MAC 0.80 (0.62-1.03) 0.08  
PBSC versus BM 0.81 (0.60-1.09) 0.16  
Female to male recipient versus other 1.11 (0.86-1.43) 0.42  
Patient CMV seropositivity 1.26 (0.98-1.63) 0.07  
Donor CMV seropositivity 0.72 (0.57-0.91) <0.01  
Time from diagnosis to allo-HSCT > median 0.99 (0.93-1.05) 0.80  
OS    
Haplo versus MSD 0.73 (0.44-1.20) 0.21  
Age (incremental age of 10 years) 1.19 (1.07-1.32) <0.01  
Year of allo-HSCT 0.98 (0.93-1.03) 0.38  
RIC versus MAC 0.79 (0.60-1.02) 0.07  
PBSC versus BM 0.82 (0.60-1.12) 0.21  
Female to male recipient versus other 1.15 (0.88-1.51) 0.30  
Patient CMV seropositivity 1.24 (0.95-1.62) 0.11  
Donor CMV seropositivity 0.77 (0.60-0.98) 0.03  
Time from diagnosis to allo-HSCT > median 0.99 (0.93-1.06) 0.84  
GRFS    
Haplo versus MSD 0.88 (0.58-1.34) 0.56  
Age (incremental age of 10 years) 1.09 (0.99-1.19) 0.07  
Year of allo-HSCT 0.96 (0.92-1.01) 0.09  
RIC versus MAC 0.78 (0.62-0.99) 0.04  
PBSC versus BM 1.13 (0.85-1.51) 0.39  
Female to male recipient versus other 1.19 (0.94-1.50) 0.14  
Patient CMV seropositivity 1.05 (0.84-1.32) 0.67  
Donor CMV seropositivity 0.80 (0.65-0.99) 0.04  
Time from diagnosis to allo-HSCT > median 0.97 (0.92-1.03) 0.28  
aGvHD II-IV    
Haplo versus MSD 2.20 (1.29-3.74) <0.01  
Age (incremental age of 10 years) 0.90 (0.78-1.03) 0.12  
Year of allo-HSCT 0.96 (0.90-1.02) 0.22  
RIC versus MAC 0.83 (0.56-1.21) 0.32  
PBSC versus BM 1.30 (0.83-2.04) 0.25  
Female to male recipient versus other 1.07 (0.73-1.55) 0.74 continued on the next page 
  
 
Patient CMV seropositivity 0.95 (0.65-1.39) 0.80 
Donor CMV seropositivity 0.94 (0.66-1.33) 0.72 
Time from diagn to allo-HSCT > median 0.95 (0.87-1.04) 0.24 
cGvHD   
Haplo versus MSD 1.02 (0.58-1.78) 0.95 
Age (incremental age of 10 years) 1.07 (0.94-1.21) 0.33 
Year of allo-HSCT 1.00 (0.94-1.06) 0.96 
RIC versus MAC 0.96 (0.68-1.36) 0.83 
PBSC versus BM 1.03 (0.68-1.56) 0.89 
Female to male recipient versus other 1.23 (0.88-1.72) 0.23 
Patient CMV seropositivity 0.87 (0.62-1.20) 0.39 
Donor CMV seropositivity 1.04 (0.76-1.42) 0.79 
Time from diagnosis to allo-HSCT > median 0.94 (0.87-1.03) 0.18 
HR: hazard ratio; CI: confidence interval; RI: relapse incidence; NRM: non-relapse mortality; LFS: leukemia free survival; OS: overall survival; GRFS: refined 
graft-versus-host dis- ease/relapse-free survival; aGvHD: acute graft-versus-host disease; cGvHD: chronic graft-versus-host disease; Haplo: haploidentical donor; 
MSD: matched sibling donor; allo- HSCT: allogeneic hematopoietic stem cell transplantation; RIC: reduced intensity conditioning regimen; MAC: myeloablative 
conditioning regimen; PBSC: peripheral blood stem cells; BM: bone marrow; CMV: cytomegalovirus. 
 
 
Propensity score matching analysis 
We were able to pair-match 183 Haplo with 364 MSD. 
The results of propensity score analysis are summarized in 
Table 4. 
In the group of patients presenting an intermediate risk 
cytogenetics, Haplo was associated with a higher risk of 
NRM (HR 2.59. 95% CI: 1.59-4.20. P<0.01), lower LFS (HR 
1.60; 95% CI: 1.15- 2.22; P<0.01) and OS (HR 1.61; 95% 
CI: 1.12-2.30; P<0.01). There was no significant association 
between Haplo grade II-IV aGvHD, cGvHD and GRFS. 
In the group of patients presenting cytogenetics classi- 
fied as high risk, Haplo was associated to higher risk of 
acute GvHD grade II-IV (HR 2.06; 95% CI: 1.14-3.75; 
P=0.02) and a trend for a lower risk of relapse (HR 0.53; 
95% CI: 0.28-1.01; P=0.053). There was no significant 
association between Haplo and other main outcomes. 
Survival curves according to the results of pair-matched 
analysis in each cytogenetic group are shown in Figure 1 
and 2. 
 
Discussion 
Allogeneic HSCT might be a curative option in patients 
diagnosed with AML and achieving CR, especially in 
those with unfavorable cytogenetics for which prognosis 
is very poor with chemotherapy alone. Use of HSCT in 
patients with intermediate risk cytogenetics is sometimes 
debated, according to the different transplant center poli- 
cies. Subsequently, for these two cytogenetic risk cate- 
gories, a donor search might be immediately launched at 
time of diagnosis.32 In the absence of a MSD, Haplo may 
represent a valid alternative, despite initial concerns being 
raised due to the high risk of graft failure and NRM in this 
setting.9 
The aim of the current study was to compare the out- 
comes of patients transplanted either from a MSD or 
Haplo donor in patients with AML in first CR. According 
to cytogenetic at time of diagnosis, AML was classified as 
intermediate or high risk. Moreover, due to a significant 
interaction according to cytogenetic risk, intermediate and 
high-risk AML were then analyzed separately. According 
to donor type, higher risk of grade II-IV aGvHD was 
reported in Haplo recipients. Furthermore, donor CMV 
 
positive serology was found as a risk factor for aGvHD, as 
already shown by others.33,34 
In agreement with previous reports,35,36 among AML 
with intermediate cytogenetic risk, the intensity of the 
conditioning regimen was associated with higher risk of 
aGvHD, as well as female to male donor, while in AML 
with high cytogenetic risk, the only factor associated with 
higher risk of aGvHD was the type of donor. Furthermore, 
stem cell sources were not influential for acute GvHD, as 
previously described.20 
No significant differences in the CI of cGvHD were 
found according to donor type. This could also be related 
to the higher proportion of BM in the Haplo group. 
Our results are in some part different to those reported 
by Luznik et al.12 Importantly, the experience reported by 
the Baltimore group is mainly in non myeloablative condi- 
tioning regimen and BM as stem cell source and this could 
in part explain the difference among our results. Also, 
being a registry study, we reported data from several 
transplant centers including different immunosuppressive 
protocols according to different Centers and as compared 
to previous reports19 and therefore no direct comparison 
could be performed. 
Compared with MSD recipients, Haplo recipients had a 
longer time to neutrophils recovery with a median time to 
engraftment of 2 days longer than MSD, in line with pre- 
vious studies;17,18 this is probably due to the higher propor- 
tion of patients receiving bone marrow graft among 
Haplos and the myelosuppression from PT-CY. 
NRM was worse in the Haplo recipients in univariate 
and multivariate analysis. When looking at cytogenetics 
groups, this result was confirmed in intermediate risk, but 
not in high risk, where Haplo and MSD had similar NRM, 
in line with previous reports.17,19,20 Furthermore, female 
donor to male recipient was associated to a higher NRM 
in intermediate AML and not in high risk AML. Therefore, 
one can speculate that the impact of female to male mis- 
match could depend on the risk of the underlying disease, 
as previously shown.36 However, a possible explanation to 
the results in the high-risk group might be related to the 
low number of patients, preventing us to make definitive 
conclusions. 
Death from infections was more common in Haplo 
transplants than MSD maybe due to a slower immune 
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Table 4. Propensity score analysis for main outcomes after allo-HSCT according to donor type in patients with intermediate (a) and high risk (b) 
AML. 
 
A) Outcome RI % NRM % LFS % OS % Gr. II-IV cGvHD% GRFS% 
±s.d. % ±s.d. ±s.d. ±s.d. aGvHD % ±s.d. ±s.d. ±s.d. 
Haplo 18±6 26±8 56±8 68±9 29±7 30±9 45±10 
MSD 21±5 10±4 69±6 79±5 21±5 35±6 53±7 
HR (95   CI) 1.04 (0.65-1.66)  2.59 (1.59-4.20) 1.60 (1.15-2.22) 1.60 (1.12-2.29) 1.49 (0.95-2.31) 0.82 (0.54-1.24) 1.27 (0.94-1.71) 
P 0.86 <0.01 <0.01 <0.01 0.07 0.37 0.11 
 
B) Outcome RI % NRM % LFS % OS % Gr. II-IV cGvHD% GRFS% 
±s.d. ±s.d. ±s.d. ±s.d. aGvHD % ±s.d. ±s.d. ±s.d. 
Haplo 22±11 17±10 61±13 67±13 37±12 37±13 51±13 
MSD 39±10 13±7 48±10 57±9 21±7 31±10 41±10 
HR (95   CI) 0.53 (0.28-1.00)  1.07 (0.45-2.51) 0.68 (0.40-1.13) 0.68 (0.39-1.19) 2.06 (1.13-3.74) 0.98 (0.54-1.77) 0.82 (0.52-1.28) 
P 0.05 0.87 0.14 0.18 0.01 0.95 0.39 
RI: relapse incidence; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS: refined graft-versus-host-free relapse free survival; Gr. II-IV 
aGvHD: grade II- IV acute graft-versus-host disease; cGvHD: chronic graft-versus-host disease; HAPLO: haploidentical donor; MSD: matched sibling donor; HR: 
hazard ratio; CI: confidence interval. 
 
 
 
reconstitution in Haplo setting, also favored by the use of  note, they also found higher incidence of grade II-IV 
additional high doses of immunosuppressive agents as  aGvHD, without differences in cGvHD, and higher NRM 
compared to MSD. However, as ours is  a registry-based  in the Haplo setting. In our study, as in Bashey population, 
study, details on type of infections were not available.  the time from diagnosis to transplant was longer for Haplo 
Importantly, the type of donor did not influence the risk than MSD and this could have negatively affected out- 
of relapse in intermediate AML. Recently, Ringden et al.37  comes of transplant. In multivariate analysis, incremental 
published no difference in leukemic relapse between MSD  age produced effects on LFS and OS, regardless of cytoge- 
and Haplo. On the other hand, in high-risk AML, we netics, in line with others.40 
found a trend for higher RI in MSD recipients; this could Our data were analyzed using the propensity score 
reflect a lower immunogenicity of MSD transplant in analysis in order to balance characteristics of the two pop- 
AML with more biological aggressive characteristics. Our ulations. The matched pair analysis confirmed the results 
results should be taken with caution as there are impor- of higher aGvHD incidence in Haplo compared to MSD, 
tant factors that we were not able to take into account, and confirmed the main outcome results that we found in 
such as molecular biology data, important for disease standard analysis, for both intermediate and high risk 
stratification. Risk group was, indeed, defined according AML. 
to cytogenetics at diagnosis.   Given the main finding of our study, outcomes of trans- 
In intermediate AML, a RIC regimen was associated to plantation from Haplo versus MSD depend on the 
higher risk of relapse as previously described,35  while in  leukemic cytogenetics risk. Intermediate AML outcomes 
high-risk AML, the type of conditioning regimen affected  were better in the MSD setting as compared to Haplo 
neither relapse nor GvHD incidence In this setting, CMV  with no significant differences in RI among the two types 
serology and incremental age were the only factors affect-  of donor. Whilst in high-risk AML, there were no signifi- 
ing risk of relapse, while the type of donor was the only  cant differences in the main transplantation outcomes 
related to risk of GvHD.  between Haplo and MSD, except for the lower risk of 
The probability of LFS was lower in Haplo, in line with relapse in the Haplo group. However, we acknowledge 
previous reports.37  that the number of patients with high risk cytogenetics in 
In a retrospective study from a single center, Bashey et our study was low and, consequently, the statistical 
al.17 reported outcomes of 475 patients receiving unmanip- power was too. 
ulated Haplo transplant using PT-CY in comparison to In conclusion, our results underline that matched sibling 
MSD or 10/10 matched unrelated donors. This series on donor remain the first donor choice for AML patients in 
patients with lymphoid and myeloid malignancies includ- first CR when available. It should be of interest to further 
ed 170 patients with AML. In line with our results, OS investigate the role of Haplo  in  this  setting  with  well- 
was superior in MSD as compared to Haplo recipients. Of designed prospective studies. 
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